The U.S. Food and Drug Administration approved Paxlovid on May 25. Until then, the oral COVID-19 treatment for adults has been used under an Emergency Use Authorization. According to the most recent data (from the end of April), approximately 14,500 cases of COVID-19 are reported each week; this understates cases because most test results are not reported. The U.S. government will continue to oversee the distribution of Paxlovid and eligible individuals will receive it at no charge (except possible administrative fees).